Publications

In vitro Activity of Gepotidacin against Escherichia coli Causing Urinary Tract Infections in the United States, Including Molecularly Characterized, Fluoroquinolone-Resistant Subsets. Lead author: RE Mendes presented at IDWeek 2021, September 29-October 3, Virtual Conference

Ceftobiprole Activity against Drug-Resistant Staphylococcus aureus Clinical Isolates Collected in the United States from 2016 through 2020. Lead author: LR Duncan presented at IDWeek 2021 September 29-October 3, Virtual Conference

Antimicrobial Activity of Ceftaroline and Comparator Agents against Ceftriaxone-Nonsusceptible Streptococcus pneumoniae from the United States (2008-2020). Lead author: HS Sader presented at IDWeek 2021, September 29-October 3, Virtual Conference

In Vitro Activity of Lefamulin against Staphylococcus aureus Isolated from the Lower Respiratory Tract of Children with Cystic Fibrosis. Lead author: HS Sader presented at IDWeek 2021, September 29-October 3, Virtual Conference

In Vitro Activity of Cefiderocol and Comparator Agents against Molecularly Characterized Carbapenem-resistant Enterobacterales Clinical Isolates Causing Infection in United States Hospitals (2020). Lead author: RE Mendes presented at IDWeek 2021, September 29-October 3, Virtual Conference

In vitro Activity of Tebipenem against Relevant Clinical Isolates in the Presence of Pulmonary Surfactant. Lead author: SJR Arends presented at IDWeek 2021, September 29-October 3, Virtual Conference

Tebipenem In Vitro Activity against a Collection of Pathogens Responsible for Urinary Tract Infections in the US. Lead author: RE Mendes presented at IDWeek 2021, September 29-October 3, Virtual Conference

Cefiderocol In Vitro Activity against Molecularly Characterized Acinetobcter baumannii-calcoaceticus Complex and Pseudomonas aeruginosa Clinical Isolates Causing Infection in United States Hospitals (2020). Lead author: RE Mendes presented at IDWeek 2021, September 29-October 3, Virtual Conference

Activity of Meropenem-Vaborbactam and Comparator Agents against Carbapenemase-Negative, Carbapenem-Resistant Enterobacterales from US Hospitals. Lead author: M Castanheira presented at IDWeek 2021, September 29-October 3, Virtual Conference

Activity of Cefiderocol and Comparators against Gram-Negative Isolates from US Patients Hospitalized with Pneumonia. Lead author: D Shortridge presented at IDWeek 2021, September 29-October 3, Virtual Conference

Antimicrobial Activity of Aztreonam-Avibactam and Comparator Agents against Gram-Negative Bacteria Isolated from Bloodstream and Complicated Urinary Tract Infections in Europe, Asia, and Latin America (2019-2020). Lead author: HS Sader presented at IDWeek 2021, September 29-October 3, Virtual Conference

Activity of Rezafungin and Comparator Antifungal Agents Tested Against a Worldwide Collection of Contemporaneous Invasive Fungal Isolates (2019-2020). Lead author: CG Carvalhaes presented at IDWeek 2021, September 29-October 3, Virtual Conference

Epidemiology and Susceptibility Profiles of ST131-025b Escherichia coli Detected Among Cephalosporin- and/or Carbapenem-Resistant Isolates Collected in United States Hospitals. Lead author: M Castanheira presented at IDWeek 2021, September 29-October 3, Virtual Conference

Occurrence of β-Lactamases among Enterobacterales Isolated from United States Hospitals: Results of the INFORM Surveillance Program for Ceftazidime-Avibactam. Lead author: M Castanheira presented at IDWeek 2021, September 29-October 3, Virtual Conference

In Vitro Analysis of AmpC β-lactamase Induction by Tebipenem in Enterobacterales and Pseudomonas aeruginosa. Lead author: RE Mendes presented at IDWeek 2021, September 29-October 3, Virtual Conference

Optimization of a 96-Well Plate Format Assay to Evaluate Concentration-Dependent Activity of a Monoclonal Antibody against the O Antigen 025b from ST131-H30 Escherichia coli. Lead author: J Lindley presented at IDWeek 2021, September 29-October 3, Virtual Conference

Analysis of Resistance to Oral Standard of Care Antibiotics for Urinary Tract Infections Caused by Escherichia coli and Staphylococcus saprophyticus Collected Worldwide between 2019-2020. Lead author: SJR Arends presented at IDWeek 2021, September 29-October 3, Virtual Conference

In vitro Activity of Tebipenem, an Orally Available Carbapenem Agent, against a Collection of Surveillance Gram-positive Clinical Isolates. Lead author: SJR Arends presented at IDWeek 2021, September 29-October 3, Virtual Conference

Update on the In Vitro Activity of Ceftaroline against Staphylococcus aureus from United States (US) Medical Centers Stratified by Infection Type (2018-2020). Lead author: HS Sader presented at IDWeek 2021, September 29-October 3, Virtual Conference

Antimicrobial Activity of Plazomicin against Multidrug-resistant Enterobacterales: Results from 3 Years of Surveillance in Hospitals in the United States (2018-2020). Lead author: HS Sader presented at IDWeek 2021, September 29-Ocrtober 3, Virtual Conference

Molecular Epidemiology of Escherichia coli Causing Urinary Tract Infections in United States and In Vitro Activity of Tebipenem, Including against Strain Lineage and Resistant Subsets (2018-2020). Lead author: RE Mendes presented at IDWeek 2021, September 29-October 3, Virtual Conference

Oritavancin Activity Against Methicillin-Resistant S. aureus (MRSA) Isolates Causing Skin and Skin Structure Infections in US Hospitals (2017-2019). Lead author: CG Carvalhaes presented at IDWeek 2021, September 29-October 3, Virtual Conference

Minocycline activity against Acinetobacter baumannii-calcoaceticus species complex, Burkholderia cepacia complex, and Stenotrophomonas maltophilia from US hospitals. Lead author: D Shortridge, presented at IDWeek 2021, September 29-October 3, Virtual Conferece

Activity of meropenem/vaborbactam and comparators against Gram-negative isolates from Eastern and Western European patients hospitalized with pneumonia including ventilator-associated pneumonia (2014-19). by Shortridge D, Carvalhaes C, Deshpande L and Castanheira M. published in J Antimicrob Chemother. 2021; 76 (10): 2600-2605

Antimicrobial Susceptibility of Gram-negative Organisms from Southeast Asia. Lead author: H Sader presented at 13th International Symposium on Antimicrobial Agents and Resistance (ISAAR 2021), September 9-10, 2021, Virtual Conference
Poster #0323

Anti-staphylococcal lysin, LSVT-1701, activity: In vitro susceptibility of Staphylococcus aureus and coagulase-negative staphylococci (CoNS) clinical isolates from around the world collected from 2002 to 2019. by Huang DB, Sader HS, Rhomberg PR, Gaukel E and Borroto-Esoda K. published in Diagn. Microbiol. Infect. Dis. 2021; 101 (3): 115471

Antifungal drugs work together to treat germs causing fungal infections. by Pfaller MA, Messer SA, Deshpande LM, Rhomberg PR, Utt EA and Castanheira M. published in Future Microbiol. 2021; 16: 765-768

Intermethod Comparability Analyses of Gepotidacin Antimicrobial Susceptibility Tests Using Over 3,600 Globally-collected Clinical Isolates. Lead author: SJR Arends presented at World Microbe Forum, 20-24 June 2021, Virtual Conference

Current Epidemiology and Activity of Gepotidacin and Comparator Agents Against Escherichia coli Surveillance Isolates Causing Urinary Tract Infections in the Unites States. Lead author: RE Mendes presented at World Microbe Forum, 20-24 June 2021, Virtual Conference

Extended-spectrum beta-lactamases: An update on their characteristics, epidemiology and detection. by Castanheira M, Simner PJ and Bradford PA publised in JAC Antimicrob. Resist. 2021; 3 (3): dlab092

In Vitro Evaluation of Delafloxacin Activity when Tested against Contemporary Isolates from European Acute Skin and Skin Structure Infections: Results from the SENTRY Antimicrobial Surveillance Program (2018-2020). Lead author: D Shortridge presented at ECCMID 2021, July 9-12, Virtual Conference
Poster # 1529

Comparative activity of posaconazole and systemic azole agents against clinical isolates of filamentous fungi from a global surveillance programme. by Carvalhaes CG, Rhomberg PR, Pfaller M and Castanheira M. published in JAC Antimicrob. Resist. 2021; 3 (2): dlab088

Frequency of Occurrence and Antimicrobial Susceptibility of Bacteria Isolated from Patients Hospitalised with Bacterial Pneumonia in Western Europe and Eastern Europe: Results from the SENTRY Program (2018-2020). Lead author: H Sader presented at ECCMID 2021, July 9-12, Virtual Conference
Poster #718

Activity of Cefiderocol and Comparators against European Enterobacterales Including Carbapemen-Resistant Isolates. Lead author: D Shortridge presented at ECCMID 2021, July 9-12, Virtual Conference
Poster #1563

In Vitro Post-Antifungal Effect of Amphotericin B, Fluconazole, and Micafungin against Candida albicans, Candida glabrata, and Candida parapsilosis. Lead author CG Carvalhaes, presented at ECCMID 2021, July 9-12, Virtual Conference
Poster #1630

Azole Resistance In Candida glabrata Clinical Isolates from Global Surveillance Is Associated with Efflux Overexpression. Lead author: L Deshpande presented at ECCMID 2021, July 9-12, Virtual Conference
Poster #02265

Antimicrobial Activities of Cefepime, Meropenem, Aztreonam, and Piperacillin Combined with Nacubactam against Molecularly Characterized Enterobacterales Collected Worldwide. Lead author: HS Sader presented at ECCMID 2021, July 9-12, Virtual Conference
Poster #893

Activity of Meropenem-Vaborbactam and Comparators against European Carbapenem-Resistant Enterobacterales Isolates without a Carbapenemase. Lead author: D Shortridge presented at ECCMID 2021, July 9-12, Virtual Conference
Poster # 1047

Activity of Cefiderocol and Comparators against US Enterobacterales, Including Carbapenem-Resistant Isolates. Lead author: D Shortridge presented at ECCMID 2021, July 9-12, Virtual Conference
Poster #1591

Activity of Meropenem-Vaborbactam and Comparators against Pseudomonas aeruginosa Isolates from Patients with Pneumonia in European Hospitals. Lead author: D Shortridge presented at ECCMID 2021, July 9-12, Virtual Conference
Poster # 1048

Epidemiology and Molecular Characterization of Linezolid Non-Susceptible Enterococcus spp. Clinical Isolates from the SENTRY Antimicrobial Surveillance Program (2017-2019). Lead author: CG Carvalhaes presented at ECCMID 2021, July 9-12, Virtual Conference
Poster #051

High Prevalence of Tetracycline Resistance Genes among Escherichia coli, Klebsiella pneumoniae and Proteus mirabilis Clinical Isolates Causing Infections in Europe (2019). Lead author L Deshpande presented at ECCMID 2021, July 9-12, Virtual Conference
Poster #2235

In Vitro Activity of Gepotidacin and Comparators Against a Collection of E. coli and S. saprophyticus Urine Isolates Collected from Europe during 2019-2020. Lead author: SJR Arends, presented at ECCMID 2021, July 9-12, Virtual Conference
Poster #2122

Five Years of Analysis of the In Vitro Activity of Tedizolid against a Worldwide Collection of Indicated Species Causing Clinical Infections: Results from the Surveillance of Tedizolid Activity and Resistance (STAR) Program. Lead author: CG Carvalhaes presented at ECCMID 2021, July 9-12, Virtual Conference
Poster #264

Prevalence of CC131 and the Emergence of Other Sequence Types among Escherichia coli Isolates Causing Urinary Tract Infections from Asia-Pacific, Europe, and Latin America. Lead author: LM Deshpande presented at ECCMID 2021, July 9-12, Virtual Conference
Poster #422

Oritavancin Activity against Gram-Positive Pathogens causing Bone and Joint Infections In European Medical Centres (2015-2019). Lead author: CG Carvalhaes presented at ECCMID 2021, July 9-12, Virtual Conference
Poster #1626

Activity of KBP-7072, a Novel Aminomethylcycline Antibacterial, and Tetracycline Class Comparators Against 1,057 Bacterial Pathogens Collected Worldwide During 2019. Lead author: M Huband presented at ECCMID 2021, July 9-12, Virtual Conference
Poster #1510

Evaluation of Pleuromutilins Resistance Mechanisms Among Surveillance Clinical Isolates: Results from the Worldwide Surveillance Program for Lefamulin in 2019. Lead author: RE Mendes, presented at ECCMID 2021, July 9-12, Virtual Conference
Poster #2146

In Vitro Activity of a Novel Aminomethylcycline Antibacterial (KBP-7072) against Clinical Isolates with Molecularly Characterized Tetracycline Resistance Mechanisms. Lead author: RE Mendes presented at ECCMID 2021, July 9-12, Virtual Conference
Poster #2189

Activity of Oritavancin and Comparators against a Contemporary Collection of Enterococcus spp. Clinical Isolates from Europe (2015-2019). Lead author: CG Carvalhaes presented at ECCMID 2021, July 9-12, Virtual Conference
Poster #1616